Galantamine: Use in Alzheimer's disease and related disorders

Expert Review of Neurotherapeutics

Volumn 4, Issue 2, 2004, Pages 153-163

  Bullock, Roger ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Galantamine; Nicotinic; Vascular dementia

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CODEINE; CYTOCHROME P450; DONEPEZIL; ERYTHROMYCIN; GALANTAMINE; GLUTAMIC ACID; KETOCONAZOLE; MECAMYLAMINE; MEMANTINE; MESSENGER RNA; MONOCLONAL ANTIBODY; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; PAROXETINE; PHYSOSTIGMINE; PHYSOSTIGMINE SALICYLATE; PLASMA PROTEIN; PROTEIN; RECEPTOR SUBTYPE; RISPERIDONE; RIVASTIGMINE; SEROTONIN; TACRINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; BEHAVIOR; CAREGIVER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH ECONOMICS; HUMAN; LEWY BODY; MULTIINFARCT DEMENTIA; NERVE CELL PLASTICITY; REVIEW;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS;

EID: 1542374114     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.2.153     Document Type: Review

References (86)

1. Howes MJ, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol. Biochem. Behav. 75(3), 513-271 (2003).
2. Bosanquet N. Alzheimer's disease in the United Kingdom. Health Policy Unit, Imperial School of Medicine, London, UK (1998).
3. Mace NL, Rabins PV. The 36-hour Day: a Family Guide to Caring for Persons with Alzheimer's Disease, Related Dementing Illnesses and Memory Loss in Later Life. Johns Hopkins University Press, BA, USA (1991).
4. Förstl H, Kurz A. Clinical features of Alzheimer's disease. Eur. Arch Psych. Clin. Neurosci. 249, 288-290 (1999).
5. Barclay LL, Zemcov A, Blass JP, Sansone J. Survival in Alzheimer's disease and vascular dementia. Neurology 35, 834-840 (1985).
6. Gauthier S. Pharmacotherapy of Alzheimer's Disease. M Dunitz (Ed.). Martin Dunitz Ltd., London, UK (1998).
7. Mohs RC, Schmeidler J, Aryan M. Longitudinal studies in cognition, functional and behavioural change in patients with Alzheimer's disease. Stats Med. 19, 1401-1409 (2000).
8. Cummings JL, Kaufer DI. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 47, 876-883 (1996).
9. Melzer D, Ely M, Brayne C. Cognitive impairment in elderly people: population-based estimate of future in England, Scotland and Wales. Br. Med. J. 315, 462 (1997).
10. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414 (1982).
11. Traykova M, Traykov T, Hadjimitova V, Krikorian K, Bojadgieva N. Antioxidant properties of galantamine hydrobromide. Z. Naturforsch. 58(5-6), 361-365 (2003).
12. Greenblatt HM, Kryger G, Lewis T et al. Structure of Acetylcholinesterase complexed with (-) galantamine at 2.3 Å resolution. FEBS Lett. 463, 321-326 (1999).
13. Bickel U, Thomsen T, Fischer JP et aL Galantamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30, 447-454 (1991).
14. Thomsen T, Kaden B, Fischer JP et al. Inhibition of acteylcholinesterase activity in human brain tissue and erythrocytes by galantamine, physostigmine and tacrine. Eur. J. Clin. Chem. Clin. Biochem. 29, 487-492 (1991).
15. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 6, 75-111 (2000).
16. Perry E, Morris CM, Court JA et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64, 385-395 (1995).
17. Nordberg A, Adem A, Hardy J, Winblad B. Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci. Lett. 86, 317-321 (1988).
18. Banerjee C, Nyengaard JR, Wevers A et al. Cellular expression of α7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease - a stereological approach. Neurobiol. Dis. 7, 666-672 (2000).
19. Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10, 93-107 (1994).
20. Sahakian BJ, Jones GMM. The effects of nicotine on attention, information processing and working memory in patients with dementia of the Alzheimer type. In: Effects of Nicotine on Biological Systems. Adlkofer F, Thruau K (Eds). Birkhauser Verlag, Basel, Switzerland (1991).
21. Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer's disease. Drug Disc. Today 1, 53-59 (1996).
22. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11(Suppl. 1), 11-18 (2000). Summarizes the important role of the nicotinic receptor as a target for treatment in Alzheimer's diesease (AD).
23. Maelicke A, Samochocki M, Jostock R et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry 49, 279-288 (2001).
24. Woodruff-Pak DS, Vogel RW III, Wenk GL. Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase and nicotinic acetylcholine receptors. Neuroscience 117(2), 439-447 (2003).
25. Schrattenholtz A, Pereira EFR, Roth U et al. Agonist responses on neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49(1), 1-6 (1996).
26. Schrattenholz A, Godovac-Zimmerman J, Schafer H-J et al. Photoaffinity labelling of Torpedo acetylcholine receptors by physostigmine. Eur. J. Biochem. 216, 671-677 (1993).
27. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in antinerve growth factor mice Proc. Natl. Acad. Sci. USA 99(19), 12432-12437 (2002).
28. Arroyo G, Aldea M, Fuentealba J, Garcia AG. Nicotinic receptor, galantamine and Alzheimer's disease. Rev. Neurol. 34(11), 1057-1065 (2002).
29. Arias E, Ales E, Gabilan NH et al. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46(1), 103-114 (2004). Links galantamine with neuroprotection in the laboratory and encourages the design of a proper disease modification study in man.
30. Bickel U, Thomsen T, Weber W et al. Pharmacokinetics of galantamine in humans and corresponding cholinesterase Clin. Pharmacol. Ther. 50, 420-428 (1991).
31. Wood DM, Ford JM, Willcock GK et al. Plasma protein binding of galantamine: a potential agent for the treatment of Alzheimer's disease. Eur. J. Clin. Pharmacol. 52(Suppl), A161 (1997).
32. Mihailova D, Yamboliev I. Pharmacokinetics of galantamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. Pharmacology 32, 301-306 (1986).
33. Janssen Pharmaceutica. Reminyl™ (galantamine) tablets prescribing information 11 July 2000. Janssen Pharmaceutica, NV, USA (2000).
34. Raskind MA, Peskind ER, Wessel T, Yuan W on behalf of the Galantamine USA-1 Study Group: Galantamine in AD - a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 54, 2261-2268 (2000).
35. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. Neurology 54, 2269-2276 (2000).
36. Rogers S, Friedhoff L. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur. Neuropsychopharmacol. 8(1), 67-75 (1998).
37. Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord. 10, 237-244 (1999).
38. Robillard A, McKelvey R, Nasreddine Z. Galantamine improves quality of sleep in patients previously treated with donepezil (preliminary results). Presented at the 14th Annual Meeting of the American Association for Geriatric Pychiatry, San Francisco CA, USA, February 23-26 (2001).
39. Mintzer J, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int. J. Geriatr Psych. 18(4), 292-297 (2003).
40. Rasmusen L, Yan B, Robillard A, Dunbar F. Effects of washout and dose-escalation periods on the efficacy, safety and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clin. Ther. 23(Suppl. A), A25-A30 (2001).
41. Wilkinson D, Murray JR. Galantamine: a randomised, double-blind, dose-finding trial in patients with Alzheimer's disease. Int. J. Psych. 16(9), 852-857 (2001).
42. Wilcock GK, Lilienfeld S, Gaens E on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: a multicentre randomised controlled trial. Br. Med. J. 321, 1445-1449 (2000).
43. Rockwood K, Mintzer J, Truyen L. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J. Neurol. Neurosurg. Psychiatry 71, 589-595 (2001).
44. Mintzer J, Kershaw P. Galantamine provides cognitive and functional benefits over 12 months in patients with Alzheimer's disease. Presented at the 125th Annual Meeting of the American Neurological Association, Boston, MA, USA. 15-18 October (2000).
45. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am. J. Psych. 141, 1356-1364 (1984).
46. Schneider LS, Olin JT, Doody RS et al. Validity and reliability of the Alzheimer's disease Co-operative Study - Clinical Global Impression of Change, The Alzheimer's disease Co-operative Study. Alzheimer Dis. Assoc. Disord. 11(Suppl. 2), S22-S32 (1997).
47. Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K. Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. Dement. Geriatr. Cogn. Disord. 15(1), 26-33 (2003).
48. Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease Co-operative Study. Alzheimer Dis. Assoc. Disord. 11(Suppl. 2), S33-S39 (1997).
49. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am. J. Occup. Ther. 53, 471-481 (1999).
50. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48(Suppl. 6), S10-S16 (1997).
51. Huang F, Lasseter KC, Janssens L, Verhaeghe T, Lau H, Zhao Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J. Clin. Pharmacol. 42(12), 1341-1351 (2002).
52. Blesa R. Galantamine: therapeutic effects beyond cognition. Dement. Geriatr. Cogn. Disord. 11(Suppl. 1), 28-34 (2000).
53. Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin. Pharmacol. Ther. 58, 228-236 (1995).
54. Wilcock GK, Lilienfeld S, Kershaw P. Galantamine produces cognitive, functional and global benefits in patients with Alzheimer's disease: pooled data from two 6-month studies. Presented at the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, Sweden, April (2000).
55. Lilienfeld S, Parys W. Galantamine: additional benefits to patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11(Suppl. 1), 19-27 (2000).
56. Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement. Geriatr. Cogn. Disord. 15(2), 79-87 (2003).
57. Farlow MR, Lahiri DK, Poirier J et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann. NY Acad. Sci. 802, 101-110 (1996).
58. Stern RG, Mohs RC, Dividson M et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am. J. Psychiatry 151, 390-396 (1994).
59. Raskind M, Truyen L. The cognitive and functional benefits of galantamine; a 12-month study in Alzheimer's disease. Presented at the 125th Annual Meeting of the American Neurological Association. Boston, MA, USA, October 15-18 (2000).
60. Tariot P, Winblad B. Galantamine, a novel treatment for Alzheimer's disease: a review of long-term benefits to patients and caregivers. In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Iqbal K, Sisodia SS, Winblad B (Eds). John Wiley & Sons Ltd, NJ, USA, 707-723 (2001).
61. Torfs K, Feldman H. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: two randomized placebo-controlled studies. Presented at the World Alzheimer's Congress (WAC). Washington DC, USA, July (2000).
62. Winblad B. Maintaining functional and behavioral abilities in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 15(Suppl. 1), S34-S40 (2001).
63. Lilienfeld S, Gaens E. Galantamine alleviates caregiver burden in Alzheimer's disease: a 12-month study. Presented at the 5th Congress of the European Federation of Neurological Societies [EFNS] Copenhagen, Denmark, October 14-18 (2000).
64. Wilcock GW, Truyen L, Lilienfeld S, Mahableshwarkar AR. Long-term cognitive effects of galantamine in the treatment of mild-to-moderate Alzheimer's disease: evidence from 48 months of treatment. Presented at the American Psychiatric Association 156th Annual Meeting. San Francisco, CA, USA, May 17-22 (2003).
65. Soininen H, Martin S, Bullock R et al. First head-to-head study comparing the efficacy of donepezil and galantamine in Alzheimer's disease. 15th Congress of the European College of Neuropsychopharmacology. Barcelona, Spain, October (2002).
66. Wilcock G, Howe I, Coles H et al. and members of the GAL-GBR-2 Study Group. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20, 777-789 (2003). The first long-term comparison study of two acetylcholinesterase inhibitors, one with and one without nicotinic modulation which produced cognitive results to show the nicotinic effect is measurable in man.
67. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J. Neurosci. 20(3), 1208-1215 (2000).
68. Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359, 1283-1290 (2002). The first published data showing the positive effect of a cholinesterase inhibitor in cerebrovascular disease.
69. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfield S, Damarju CV, for the GAL-INT-6 Study Group. Open-label extension trial of galantamine probable vascular dementia and mixed dementia. Clin. Ther. 25, 1765-1782 (2003).
70. Kurz A, Erkinjuntti T, Bullock R et al. Long-term safety and efficacy of galantamine in the treatment of probable vascular dementia and Alzheimer's disease with cerebrovascular disease: an interim analysis. Presented at the 16th Annual meeting of the American Association of Geriatric Psychiatry, Hawaii, USA, March (2003).
71. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Use of galantamine to treat vascular dementia. Lancet 360(9344), 1512-1513 (2002).
72. Zhu L, Fratiglioni L, Guo Z et al. Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project. Neurology 54(11), 2103-2107 (2000).
73. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Sys. Rev. (3), CD003672 (2003).
74. Edwards K, Hershey I, Lichter D et al. Galantamine in the management of dementia with Lewy bodies. Presented at the American Psychiatric Association 156th Annual Meeting, San Francisco, CA, USA, May 17-22 (2003).
75. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien J. Clinical predictors of response to acetylcholinesterase inhibitors, experience from routine use in Newcastle. Int. J. Ger. Psychiatry 18, 879-886 (2003).
76. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin. Neuropharmacol. 25(5), 272-275 (2002).
77. Allen T, McAvoy JP, Keefe R et al. Galantamine improves cognition in patients with schizophrenia. Presented at the American Psychiatric Association 156th AnnualMeeting, San Francisco, CA, USA, May 17-22 (2003).
78. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. Br. Med. J. 325(7377),1422 (2002).
79. Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am J Public Health 77, 1169-1175 (1987).
80. Hux MJ, O'Brien BJ, Iskediian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 159, 457-469 (1998).
81. Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis. Assoc. Disord. 13, S9-S19 (1999).
82. Caro JJ, Getsios D, Migliaccio-Walle D et al. Assessment of health economics in Alzheimer's disease (AHEAD) based on the need for full time care. Neurology 57, 964-971 (2001). A robust economic model that shows how galantamine can positively affect the cost of treatment in AD.
83. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock RA for the AHEAD Study Group. Assessment of Health Economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int. J. Ger. Psych. 18, 740-747 (2003).
84. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int. J. Clin. Prac. 127, 64-72 (2002).
85. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst. Rev. (3), CD001747 (2003). A full Cochrane review that supports the efficacy of galantamine when scrutinized using strict evidence-based criteria.
86. Wenk GL, Quack G, Moebius HJ, Danysz W. No interaction of memantme with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 66(12), 1079-1083 (2000).